Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Nicotine in Schizophrenia
Robert E. Featherstone, Steven J. Siegel
International review of neurobiology (2015), pp. 23-78
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Marco Solmi, Andréa Murru, Isabella Pacchiarotti, et al.
Therapeutics and Clinical Risk Management (2017) Vol. Volume 13, pp. 757-777
Open Access | Times Cited: 356
C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review
Guillaume Fond, Christophe Lançon, Pascal Auquier, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 75
Cognitive and functional deficits in people with schizophrenia: Evidence for accelerated or exaggerated aging?
Philip D. Harvey, Jennifer B. Rosenthal
Schizophrenia Research (2017) Vol. 196, pp. 14-21
Closed Access | Times Cited: 70
Early auditory processing dysfunction in schizophrenia: Mechanisms and implications
Clément Dondé, Joshua T. Kantrowitz, Alice Medalia, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 148, pp. 105098-105098
Open Access | Times Cited: 21
Mismatch negativity in preclinical models of schizophrenia
Robert E. Featherstone, Olya Melnychenko, Steven J. Siegel
Schizophrenia Research (2017) Vol. 191, pp. 35-42
Closed Access | Times Cited: 61
Novel Pharmacotherapies in Parkinson’s Disease
Yousef Tizabi, Bruk Getachew, Michael Aschner
Neurotoxicity Research (2021) Vol. 39, Iss. 4, pp. 1381-1390
Open Access | Times Cited: 34
A systematic review of digital interventions for smoking cessation in patients with serious mental illness
Luis Martínez Agulleiro, Bhagyashree Patil, Joseph Firth, et al.
Psychological Medicine (2023) Vol. 53, Iss. 11, pp. 4856-4868
Open Access | Times Cited: 13
Nucleus Accumbens Proteome Disbalance in an Adolescent Mouse Model of Schizophrenia and Nicotine Misuse Comorbidity
Thainá P. Souza, Andrés Rodríguez-Vega, Ana Carolina Dutra-Tavares, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 901-901
Open Access
Smoking and Serum Lipid Profiles in Schizophrenia
Hui-Mei An, Yun-Long Tan, Shu-ping Tan, et al.
Neuroscience Bulletin (2016) Vol. 32, Iss. 4, pp. 383-388
Open Access | Times Cited: 34
The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review
Clément Dondé, Jérôme Brunelin, Marine Mondino, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 118, pp. 121-133
Open Access | Times Cited: 30
Effect of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking in Patients with Schizophrenia.
Wanli Huang, Fang Shen, Jiangtao Zhang, et al.
PubMed (2016) Vol. 28, Iss. 6, pp. 309-317
Closed Access | Times Cited: 30
Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia
Joëlle Choueiry, Crystal Blais, Dhrasti Shah, et al.
International Journal of Psychophysiology (2019) Vol. 145, pp. 70-82
Closed Access | Times Cited: 20
Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort
G. Fond, Fabrice Berna, M. Andrianarisoa, et al.
European Archives of Psychiatry and Clinical Neuroscience (2017) Vol. 267, Iss. 5, pp. 465-472
Closed Access | Times Cited: 20
Impact of Nicotine on Cognition in Patients With Schizophrenia: A Narrative Review
Violeta Spasova, Saqib Mehmood, Amjad Minhas, et al.
Cureus (2022)
Open Access | Times Cited: 10
Nicotinic Receptor Intervention in Parkinson's Disease: Future Directions.
Yousef Tizabi, Bruk Getachew
PubMed (2017) Vol. 1, Iss. 1, pp. 14-19
Closed Access | Times Cited: 17
The association among smoking, HSV-1 exposure, and cognitive functioning in schizophrenia, bipolar disorder, and non-psychiatric controls
Faith Dickerson, Maria Adamos, Emily Katsafanas, et al.
Schizophrenia Research (2016) Vol. 176, Iss. 2-3, pp. 566-571
Closed Access | Times Cited: 16
Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease
Kevin R. Ward, Robert E. Featherstone, Melissa J. Naschek, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 93, pp. 84-92
Closed Access | Times Cited: 14
The effects of a novel inhibitor of tumor necrosis factor (TNF) alpha on prepulse inhibition and microglial activation in two distinct rodent models of schizophrenia
Heath W Shelton, S. Prasad Gabbita, W. Drew Gill, et al.
Behavioural Brain Research (2021) Vol. 406, pp. 113229-113229
Open Access | Times Cited: 12
Effects of an adenosine A2A agonist on the rewarding associative properties of nicotine and neural plasticity in a rodent model of schizophrenia
W. Drew Gill, Heath W Shelton, Katherine C. Burgess, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 137-144
Open Access | Times Cited: 12
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry
Joshua T. Kantrowitz, Daniel C. Javitt
Advances in neurobiology (2024), pp. 801-828
Closed Access | Times Cited: 1
Nicotine’s Effects on Schizophrenia-like Symptoms in a Mice Model: Time Matters
Ana Carolina Dutra-Tavares, Luciana Araújo Couto, Thainá P. Souza, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 855-855
Open Access | Times Cited: 1
Substance Use Disorders and Schizophrenia
Marc W. Manseau, Michael P. Bogenschutz
FOCUS The Journal of Lifelong Learning in Psychiatry (2016) Vol. 14, Iss. 3, pp. 333-342
Open Access | Times Cited: 8
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance
Andrea de Bartolomeis, Felice Iasevoli, Federica Marmo, et al.
European Neuropsychopharmacology (2018) Vol. 28, Iss. 4, pp. 538-559
Closed Access | Times Cited: 8
CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study
Joëlle Choueiry, Crystal Blais, Dhrasti Shah, et al.
Psychopharmacology (2020) Vol. 237, Iss. 12, pp. 3665-3687
Closed Access | Times Cited: 7
Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model
Ana Carolina Dutra-Tavares, Alex C. Manhães, Keila A. Semeão, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0257986-e0257986
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top